A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisInterferon beta for secondary progressive multiple sclerosisCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemCost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.[Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis].Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyMicroglial TIR-domain-containing adapter-inducing interferon-β (TRIF) deficiency promotes retinal ganglion cell survival and axon regeneration via nuclear factor-κB.Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyInterferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Evaluating the safety of β-interferons in MS: A series of nested case-control studies.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].Towards the Application of Human Defensins as Antivirals.Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon
P2860
Q22252598-18FB811F-9057-4FA1-93CF-558548B6CCC0Q24203879-7C3ED11D-D8E3-4C48-B4B0-AE4E06D6F2C5Q28066906-9B9FD8BE-E9E7-4C47-9C3C-4A852364F467Q30651607-1167A07B-15E2-4F14-9371-C670B576219EQ34325221-60503D76-9A84-4D17-AD3F-A101FD294D66Q36045080-1BAEDD4A-C2F6-4069-8A04-AF5EC4D54C59Q36171531-B8D6E905-2B59-4C1F-8F86-F5A28DC9CCE6Q36317535-8D6E7E19-6343-47BF-9071-D7B4063ADDCFQ36731484-44A155A0-A5A9-406C-959A-249A85E819DDQ37310556-F86C09FB-0CD2-47ED-914E-D715D943AB40Q38218692-0150AAC2-4B5E-41EF-AC64-E83F9F331CE4Q38252979-101F3F64-60A7-47DA-9D5D-F97D536DD393Q38788562-66A2AAB9-723E-4CF0-8593-1221075C692DQ45155454-147C4427-7FC3-4B5A-B858-434CD51A3184Q47557198-5ABB234C-26B6-485A-981A-D95A440BAF74Q52677983-EB5F0E7E-C1D3-41A2-A966-6374177A2D6CQ52855510-350AC136-9596-4392-960A-1A8B5F627A55Q59125930-6E4A6BE3-9EBC-4A3B-B5A5-28AF1FF41723
P2860
A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A meta-analysis of the efficac ...... and by drug and disease type.
@ast
A meta-analysis of the efficac ...... and by drug and disease type.
@en
A meta-analysis of the efficac ...... and by drug and disease type.
@nl
type
label
A meta-analysis of the efficac ...... and by drug and disease type.
@ast
A meta-analysis of the efficac ...... and by drug and disease type.
@en
A meta-analysis of the efficac ...... and by drug and disease type.
@nl
prefLabel
A meta-analysis of the efficac ...... and by drug and disease type.
@ast
A meta-analysis of the efficac ...... and by drug and disease type.
@en
A meta-analysis of the efficac ...... and by drug and disease type.
@nl
P1476
A meta-analysis of the efficac ...... and by drug and disease type.
@en
P2093
Shekoufeh Nikfar
P304
P356
10.1016/J.CLINTHERA.2010.10.006
P577
2010-10-01T00:00:00Z